SLU-PP-332 Peptide: Research Overview, Purity Data and Where to Buy

SLU-PP-332 is not a peptide. It sits in peptide catalogs, turns up in peptide discussions, and gets searched alongside peptides. Chemically it's a small molecule: a synthetic pan-agonist of the estrogen-related receptors (ERRalpha, ERRbeta and ERRgamma), a family of orphan nuclear receptors. That single fact changes how SLU-PP-332 is stored, solubilised and verified.

We supply research-grade compounds to laboratories, and SLU-PP-332 generates more confused handling questions than almost anything else in the catalog. All products are sold for laboratory research use only and are not for human consumption.

What is SLU-PP-332?

SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors, orphan nuclear receptors that drive transcription of genes tied to oxidative metabolism and mitochondrial function. The published work on SLU-PP-332 is preclinical, conducted in cell and rodent models. It's a research chemical, not an approved drug, and credible supply arrives with a lot-specific certificate of analysis.

The common over-simplification is calling SLU-PP-332 an 'exercise mimetic' and stopping there. That phrase describes a transcriptional pattern observed in rodent muscle, not a confirmed outcome in people, and the ERR pathway it engages reaches well beyond skeletal muscle. This hub covers the receptor pharmacology, what the indexed literature actually examines, laboratory handling and storage, how per-lot purity gets documented, regulatory status, and what ordering for research involves.

A nuclear receptor agonist, not a receptor peptide

SLU-PP-332 belongs to a compound class defined entirely by its target: the estrogen-related receptors ERRalpha, ERRbeta and ERRgamma (gene designations NR3B1, NR3B2 and NR3B3). These are orphan nuclear receptors, meaning no endogenous hormone ligand has been confirmed for them. Despite the name, they don't bind estrogen.

ERRs work inside the cell. They bind DNA directly at ERR response elements and switch on transcription of genes involved in oxidative phosphorylation, mitochondrial biogenesis and fatty acid oxidation. Their activity is governed largely by coactivator availability, principally PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the same coactivator induced in skeletal muscle by endurance exercise. SLU-PP-332 is described in the literature as a synthetic agonist that raises ERR transcriptional activity directly, rather than depending on coactivator induction to get there.

That distinction matters for anyone benchmarking SLU-PP-332 against peptide research tools. A mitochondrial-derived peptide such as MOTS-c is a 16-amino-acid sequence handled like a protein: temperature-sensitive, aqueous-soluble, vulnerable to denaturation. SLU-PP-332 is a stable organic small molecule with the solubility behaviour of an organic compound, which is precisely why its storage and solubilisation workflow looks nothing like a peptide workflow. Our team fields that mix-up most weeks, and it's the root cause of more wasted material than any other single error.

What the published literature on this compound examines

Every study we can point to is preclinical. The indexed record on PubMed is dominated by cell-model and rodent work out of academic nuclear-receptor pharmacology groups, and the compound identifier itself is reported to reflect its university origin at Saint Louis University.

Broad themes recur across that body of work: skeletal muscle oxidative capacity and running-endurance phenotypes in mice, cardiac models including heart failure, and metabolic parameters in diet-induced obesity models. Research suggests ERR agonism shifts muscle transcriptional programs toward oxidative metabolism, which is the mechanistic reason the exercise-mimetic label got attached in the first place (see the indexed ERR agonist literature). Endpoints are reported as changes in gene expression, mitochondrial markers and functional performance in animals.

What the literature does not contain, as far as we can establish, is published human clinical trial data on SLU-PP-332. No regulatory authority has approved it for any indication in any species. Any statement about what SLU-PP-332 does in people is an extrapolation across species, not a finding.

Honestly, though: reading the primary sources beats reading supplier copy, including ours. Pull the indexed papers, check the species, the model system, the duration and the measured endpoints, then decide whether the design maps onto your own research question. A compound that performs in a transgenic mouse line tells you very little about a primary human cell assay.

Laboratory handling and storage basics

Treat SLU-PP-332 as a small-molecule solid, not as a lyophilised peptide. Solid material in this chemical class is commonly stored desiccated at -20degC, protected from light and moisture, with stock solutions prepared in an organic solvent such as DMSO (dimethyl sulfoxide), split into single-use aliquots, and held at -80degC to limit repeated freeze-thaw cycles.

Here's the error we see most: a lab receives SLU-PP-332 alongside peptide orders and reaches for bacteriostatic water out of pure habit. Aqueous solubility for organic small molecules of this type is typically poor. The material either refuses to go into solution or appears to dissolve and then crashes out of suspension, and at that point the vial is compromised in a way that no visual check will reliably confirm. Peptide reconstitution habits do not transfer to SLU-PP-332, and nothing about the two workflows is interchangeable.

One more handling point that gets skipped: moisture ingress. Hygroscopic solids pull water from ambient air every time a cold vial is opened before it reaches room temperature, and condensation inside the vial degrades both weighing accuracy and long-term stability. Letting sealed material equilibrate before opening is a one-minute step that protects an entire lot.

Always defer to the product documentation and the lot-specific certificate for the material actually shipped. Vial contents, physical format and solvent guidance are documented per lot, not per product line.

How purity is documented, lot by lot

A certificate of analysis is only meaningful if it's tied to the lot number printed on the vial in your hand. Every lot of SLU-PP-332 we release is produced through small-batch synthesis and carries lot-specific analytical documentation: HPLC (high-performance liquid chromatography) area-percent purity, mass spectrometry identity confirmation, and physical characteristics such as appearance. Our certificate of analysis library is published so buyers can match documentation to lot before a vial is ever opened.

A detail most buyers miss entirely: the assays that validate a peptide are not the assays that validate SLU-PP-332. Amino acid analysis, Edman degradation sequencing and peptide mapping are structurally meaningless for a compound with no amino acid backbone. The relevant identity evidence is chromatographic retention behaviour plus molecular weight confirmation by mass spectrometry, read together. If a supplier's SLU-PP-332 certificate lists peptide-specific assays, you're looking at a reused template rather than real analytical data on real material.

Two other red flags worth checking before any purchase. First, a certificate with no lot number, no analysis date and no analyst or laboratory identification is a marketing document. Second, a purity figure reported without the method that produced it is uninterpretable, because area-percent by HPLC at one wavelength and purity by a different technique are not comparable numbers. We've reviewed enough third-party paperwork in this category to say the gap between suppliers is widest here, not in the compound itself.

Regulatory status and ordering for research use

SLU-PP-332 is not approved as a drug by the FDA or any comparable regulatory authority, is not a dietary ingredient, and is not a veterinary product. Its lawful status is as a research chemical supplied to laboratories, universities and qualified researchers for in vitro and in vivo model work. Nothing in this article is guidance for use in people or animals, and anyone with a question about an animal's health should talk to their veterinarian rather than treating a research compound as a therapeutic option.

Researchers sourcing SLU-PP-332 should confirm three things before ordering: that the supplier publishes lot-matched analytical documentation, that the stated chemical identity is confirmed by mass spectrometry, and that the material is synthesised in controlled small batches rather than repackaged from an unverified bulk source. Our product page for SLU-PP-332 lists the available format and links the documentation, and the wider research catalog follows the same per-lot standard across every compound we supply.

Institutional buyers have one additional step. Chemical-handling policies, waste-disposal requirements and research-use-only procurement rules vary by institution, and a compound that arrives without clearance is a compound that sits in a receiving bay.

SLU-PP-332 and related metabolic research compounds compared

These four compounds get grouped together in metabolic research shopping, yet only three of them are peptides and all four behave differently on the bench. The table below compares molecular class, research target and handling profile, because those three variables determine almost everything practical about working with them.

What if scenarios researchers actually run into

What if the vial arrives at ambient temperature?

Check the product documentation for the shipped format before assuming the material is compromised. Solid organic compounds in this class are considerably more tolerant of short ambient excursions during transit than lyophilised peptides are, which is one practical consequence of SLU-PP-332 not being a peptide. The failure mode to watch for is moisture, not heat: a vial that arrives with visible condensation or caking has a handling problem regardless of the temperature reading, and the supplier should be contacted with photographs and the lot number.

What if the powder looks different from the previous lot?

Stop, record the lot number, and compare the appearance description on both certificates before using the material. Small variations in crystalline form, colour or apparent density can reflect legitimate batch-to-batch synthesis differences, but they can equally flag a substituted source. The certificate of analysis exists precisely to resolve that question, which is why we publish ours in a searchable COA library rather than emailing them on request. If the appearance on the certificate doesn't match the vial, that discrepancy outranks any other consideration.

What if a supplier cannot produce a lot-specific certificate?

Treat the absence of lot-matched documentation as disqualifying and source elsewhere. A generic certificate covering a product line rather than a batch tells you nothing about the material actually in your hand, because synthesis variability occurs between batches, not between product names. We've reviewed supplier paperwork across this category for years, and the pattern is consistent: operations that resist lot-level transparency on SLU-PP-332 resist it on everything else too.

What if the research question requires independent verification?

Send a sample for third-party analysis and compare the results against the supplier certificate directly. Independent HPLC and mass spectrometry confirmation is standard practice for published work, and any supplier confident in its material will expect it. For studies intended for publication, independent verification of SLU-PP-332 identity and purity is increasingly treated by reviewers as part of the methods section rather than an optional extra.

The unglamorous truth about exercise mimetic research compounds

Let's be direct about this: preclinical rodent data does not predict human outcomes, and the history of metabolic pharmacology is littered with compounds that transformed mouse physiology and did nothing useful afterward. SLU-PP-332 currently sits entirely on the preclinical side of that line. The ERR mechanism is genuinely interesting and the animal work is genuinely published, but interesting mechanism plus animal data equals a research hypothesis, not a result. Anyone purchasing SLU-PP-332 expecting documented human effects is extrapolating across a species gap that has swallowed far better-funded compounds than this one.

Researchers working across metabolic pathways often run SLU-PP-332 alongside peptide tools, and our catalog reflects that: compounds such as MOTS-c and 5-Amino-1MQ sit under the same per-lot analytical standard, with the full research catalog and our purity standards documented separately for anyone comparing suppliers before committing to a research programme.

SLU-PP-332 occupies an odd place in research supply: a small molecule carrying a peptide's reputation, searched by people who mostly don't realise there's a difference. That confusion is not harmless, because it drives storage errors, solvent errors and purchases made against documentation that was never relevant to the compound in the first place. The compounds that eventually matter are the ones whose data survives translation, and this one hasn't been tested there yet. Treat it as what it is: a tool for interrogating ERR biology in a model system, with a certificate attached. All products are sold for laboratory research use only and are not for human consumption.

What are the chemical identifiers and physical characteristics of SLU-PP-332?

SLU-PP-332 is a synthetic small molecule, not a peptide, and its naming convention reflects its academic origin in medicinal chemistry work on estrogen-related receptor agonists. Because it is a defined organic compound rather than an amino acid chain, the paperwork accompanying a research lot looks different from what buyers see with peptide products: a certificate should list molecular formula, molecular weight, CAS registry number where assigned, appearance, and the analytical methods used for identity confirmation. Reputable vendors publish this alongside chromatographic data in a test report rather than asking buyers to take identity on faith.

Physically, research material is typically supplied as a solid powder, often off-white to pale yellow, and is described in supplier literature as sparingly soluble in aqueous buffer and more soluble in organic solvents such as DMSO. Those solubility characteristics drive most of the practical decisions a laboratory makes, which is why the laboratory handling material is worth reading before material arrives rather than after.

Lot documentation should also record the manufacturing date and retest date. Labs comparing available research-grade supply options should confirm that the identifiers printed on the vial label match those on the paperwork exactly, including lot number and compound name.

Which in vitro assay systems are used to characterize ERR agonists?

Characterization of estrogen-related receptor agonists in cell-free and cell-based systems generally follows a tiered approach. The first tier is biochemical: coactivator recruitment assays, often using time-resolved fluorescence resonance energy transfer, measure whether a compound promotes interaction between the receptor ligand-binding domain and peptide motifs from coactivators such as PGC-1α. Thermal shift and binding-displacement assays provide orthogonal confirmation that the molecule engages the protein rather than acting through an off-target route.

The second tier is cellular. Luciferase reporter constructs driven by ERR response elements allow relative potency comparisons across the ERRα, ERRβ, and ERRγ isoforms, which matters because selectivity profiles differ substantially among published chemical series. Quantitative PCR panels on known ERR target genes are then used to confirm that reporter activity translates to transcriptional output in a physiologically relevant cell type, commonly skeletal muscle myotubes.

Laboratories setting up this kind of work usually source material through channels built for institutional research supply so that identity and lot traceability are documented from the start. Comparing analytical paperwork across vendors, as summarized in a quality comparison, and reviewing the chromatograms in a supplier test report reduces the risk of attributing assay artifacts to the compound itself.

What downstream endpoints do laboratories measure after ERR pathway activation?

Once receptor engagement is confirmed, most preclinical programs move to functional readouts tied to mitochondrial biology. Extracellular flux analysis, commonly run on Seahorse-type instruments, measures oxygen consumption rate and extracellular acidification rate in exposed myotubes, giving a direct index of oxidative capacity. Mitochondrial DNA copy number, citrate synthase activity, and immunoblots for electron transport chain subunits are used as complementary structural measures.

Transcriptomic profiling is the other common layer. RNA sequencing or targeted panels covering fatty acid oxidation, oxidative phosphorylation, and mitochondrial biogenesis gene sets allow researchers to compare the signature produced by a nuclear receptor agonist against signatures produced by entirely different mechanisms. That comparison is why labs often run ERR agonists alongside mitochondrially encoded peptides, a contrast discussed in the SLU-PP-332 and MOTS-c comparison, or alongside cofactor-focused research materials such as those covered under NAD research supply.

Metabolomics on media and tissue extracts rounds out the picture, tracking acylcarnitines and TCA intermediates. Because these assays are sensitive to compound degradation, teams working through laboratory supply channels typically verify storage condition records on arrival and consult handling documentation before beginning long experimental series.

Is SLU-PP-332 studied in oncology research models?

Estrogen-related receptor alpha has been a subject of cancer biology research for considerably longer than any specific agonist chemistry has existed. ERRα expression has been reported in several tumor types and has been examined in the context of metabolic reprogramming, since tumor cells frequently rewire oxidative and glycolytic pathways. That history means ERR-directed tool compounds attract interest from oncology laboratories as well as metabolic ones, and both agonist and inverse-agonist chemistries have been explored in the published literature.

Researchers should be careful about directionality. A compound that activates a receptor and a compound that suppresses it are investigating opposite hypotheses, and literature on one cannot be used to predict outcomes for the other. Background on how these questions are framed is collected on the SLU-PP-332 cancer research page.

For cell line work in oncology, identity and purity documentation carries extra weight because proliferation and viability assays are highly sensitive to synthesis impurities. Laboratories should review the chromatographic data in the available test report and should order through research-focused supply channels that maintain lot traceability. Distinguishing small-molecule mechanisms from peptide mechanisms, as outlined in the MOTS-c comparison, also prevents mechanistic confusion in study design.

How should a laboratory vet a new supplier before placing a first order?

Vetting is mostly a documentation exercise. Start by asking whether the vendor will provide a lot-specific certificate of analysis before purchase rather than after, and whether that certificate names the analytical laboratory, the instrument method, and the date of analysis. Generic certificates reused across multiple lots are the single most common red flag, and the checklist on how to tell if a peptide supplier is legitimate walks through the rest of the warning signs.

Second, confirm that a real business entity exists behind the storefront: a registered company name, a physical address, and a responsive technical contact who can answer questions about analytical methods. Guidance on separating established operations from drop-shippers is covered under wholesale peptide legitimacy.

Third, check whether the vendor states a defined purity threshold and applies it consistently, since a published purity standard is easier to hold a supplier to than a marketing claim. Finally, read independent feedback with a critical eye; aggregated commentary on the SLU-PP-332 reviews page is most useful when it discusses documentation and fulfillment rather than outcomes. A small trial order verified in-house remains the strongest form of due diligence.

How do wholesale accounts and minimum order quantities work for research compounds?

Wholesale purchasing for research materials generally operates on an account basis rather than through anonymous checkout. Suppliers set up a wholesale peptide account after confirming that the buyer is a legitimate research entity, which typically means collecting business registration details, a tax identification number, and a statement describing the intended non-clinical research use. Once established, the account unlocks tiered purchasing, consistent lot allocation, and in many cases the ability to request retained samples from a specific production batch.

Minimum order quantities exist because analytical overhead does not scale down. Running HPLC and mass spectrometry on a lot costs roughly the same whether that lot is small or large, so vendors set thresholds that make full characterization economically sensible. The practical ranges and how they vary by compound class are explained under minimum order quantity policies.

Laboratories planning multi-year studies often negotiate reserved inventory so that an entire experimental series can draw from a single lot, eliminating lot-to-lot variability as a confounder. Budget planning considerations are outlined on the SLU-PP-332 pricing page, and the structural differences between retail and institutional purchasing are covered under research laboratory supply.

What compliance documentation do institutional purchasing departments request?

University and corporate purchasing offices rarely evaluate a research compound on scientific merit alone; they evaluate the vendor's paperwork. The common requests include a W-9 or equivalent tax form, proof of business registration, a certificate of insurance, and documentation of any distribution licensing the vendor holds. The licensing landscape is less uniform than buyers expect, and the background on wholesale drug distributor licensing explains which license types actually apply to non-clinical research chemicals versus finished pharmaceutical products.

Purchasing offices also ask for explicit research-use-only labeling language and will often require that packing slips and invoices carry the same designation as the product label. Where the compound is not an approved article of any kind, the vendor should be able to state that clearly rather than hedging. The current framework is summarized in the overview of research peptide legality and FDA rules.

State-level requirements add another layer, since registration obligations for distributors vary by jurisdiction; a state-specific example is available under Florida wholesale supply. Finally, institutions working with research laboratory supply channels generally want written confirmation of how lot records are retained and for how long.

How do shipping logistics and regional availability affect research orders?

Lead time is usually determined less by stock than by paperwork and transit. Domestic shipments of solid research material typically move quickly, while international shipments add customs clearance, which can require a commercial invoice, harmonized tariff codes, a safety data sheet, and a declaration that the contents are for non-clinical laboratory use only. Buyers searching for local availability often find that proximity matters less than whether the vendor maintains domestic inventory versus forwarding orders from an overseas manufacturer.

That distinction is worth probing directly. Supply chains originating with manufacturers in China are common across the industry, but a vendor that imports in bulk, stores domestically, and re-tests on arrival produces a very different customer experience than one that drop-ships individual parcels across borders. Import requirements in other jurisdictions differ again, as described for Australian research buyers.

Temperature control during transit is a legitimate question for any material with a defined storage condition. Ask whether shipments include insulated packaging and whether the vendor will replace material delayed in transit. Current fulfillment terms and stock status are listed with the available research supply options, and confirming them in writing before ordering avoids schedule disruption.

Why do results differ between laboratories using the same research compound?

Inter-laboratory variability in nuclear receptor pharmacology has several well-documented sources, and compound quality is only one of them. Cell line drift, passage number, serum lot, and media formulation all shift baseline oxidative metabolism, which directly affects the magnitude of any measured response. In rodent work, strain, housing temperature, light cycle, and diet composition are each capable of moving metabolic endpoints independently of the compound under study.

Material-side variables matter too. Residual solvent content, counterion identity, hydration state, and the presence of synthesis-related impurities can all alter effective concentration even when a certificate reports high chromatographic purity, which is why comparing analytical documentation across vendors — the exercise summarized in this quality analysis — is more informative than comparing headline purity percentages alone. A clearly published purity standard makes those comparisons meaningful.

Degradation during storage is the third contributor, and the practices described in the handling guidance are aimed at minimizing it. When laboratories report divergent outcomes in the aggregated commentary on the reviews page, the explanation is usually a combination of these factors rather than any single cause, which is why sourcing an entire study from one characterized lot remains best practice.